Loading
A phase 3 trial of Ipilimumab, Oxaliplatin and Capecitabine in gastric & gastro-oesophageal junction cancer, run by Ono Pharmaceutical Co., Ltd., active and no longer recruiting.
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) is a phase 3 interventional study registered as NCT05144854 by Ono Pharmaceutical Co., Ltd., with 626 participants enrolled, started 2021-11-05 and due to reach its primary completion in 2025-10-20. Interventions recorded: ONO-4538, Ipilimumab, Oxaliplatin, Capecitabine and S-1.
Shares Deciphera Pharmaceuticals (Ono), Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono), Ipilimumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono), Immune checkpoint inhibitors and the tag pipeline.